Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimagrumab and Tirzepatide in Adults With Obesity or Overweight Without Type 2 Diabetes
NCT06643728Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Primary completion
- Jan 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bimagrumab, tirzepatide in obesity, sponsored by Eli Lilly and Company. Started Oct 2024; status: active, not recruiting.
02
Drugs
bimagrumabtirzepatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06643728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643728.